These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8138327)

  • 1. Serotonergic mechanisms in hypertension.
    Chandra M; Chandra N
    Int J Cardiol; 1993 Dec; 42(3):189-96. PubMed ID: 8138327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and the vascular wall.
    Vanhoutte PM
    Int J Cardiol; 1987 Feb; 14(2):189-203. PubMed ID: 3818135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and sensitizing effects of serotonin agonists and antagonists on vascular smooth muscle.
    Myers JH; Mecca TE; Webb RC
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S44-8. PubMed ID: 2412057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive spinal serotonergic effect. Are S1 or S2 receptors involved?
    Berger A; Ramirez AJ
    Hypertension; 1988 Feb; 11(2 Pt 2):I182-5. PubMed ID: 3346054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between S2-serotonergic and alpha 1-adrenergic receptor activities at vascular sites.
    Van Nueten JM; Janssens WJ; Xhonneux R; Janssen PA
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S10-5. PubMed ID: 2459506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin and the heart.
    Frishman WH; Grewall P
    Ann Med; 2000 Apr; 32(3):195-209. PubMed ID: 10821327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of serotonin antagonism in the treatment of hypertension.
    Doyle AE
    Drugs; 1988; 36 Suppl 1():67-73. PubMed ID: 3240730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and the blood-vessel wall.
    Vanhoutte PM
    J Hypertens Suppl; 1986 Dec; 4(5):S112-5. PubMed ID: 3553471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Clin Physiol Biochem; 1990; 8 Suppl 3():1-18. PubMed ID: 2132170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin agonists and antagonists in experimental hypertension.
    Saxena PR; Bolt GR; Dhasmana KM
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S12-8. PubMed ID: 2446059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats.
    Azzadin A; Mysliwiec J; Wollny T; Mysliwiec M; Buczko W
    Thromb Res; 1995 Feb; 77(3):217-24. PubMed ID: 7740514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.
    van Zwieten PA; Blauw GJ; van Brummelen P
    Br J Clin Pharmacol; 1990; 30 Suppl 1(Suppl 1):69S-74S. PubMed ID: 2268509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.
    Villalón CM; Centurión D
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):45-63. PubMed ID: 17703282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
    Robertson JI
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological relevance of serotonin.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S19-25. PubMed ID: 2446063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin and preactivated platelets in essential hypertension.
    Bühler FR; Amstein R; Fetkovska N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S32-4. PubMed ID: 2446066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells.
    Contesse V; Lefebvre H; Lenglet S; Kuhn JM; Delarue C; Vaudry H
    Can J Physiol Pharmacol; 2000 Dec; 78(12):967-83. PubMed ID: 11149386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT3 receptor-active drugs alter development of spinal serotonergic innervation: lack of effect of other serotonergic agents.
    Bell J; Zhang XN; Whitaker-Azmitia PM
    Brain Res; 1992 Feb; 571(2):293-7. PubMed ID: 1535269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic hypotensive mechanism in rats: involvement of bulbospinal fibres.
    Ramirez AJ; Giarcovich SS; Enero MA
    J Hypertens Suppl; 1986 Apr; 4(1):S47-9. PubMed ID: 3457905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.